PolarityTE Inc. (PTE) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) Comparison side by side

This is a contrast between PolarityTE Inc. (NASDAQ:PTE) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) based on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PolarityTE Inc. 4.04M 43.97 110.51M -5.69 0.00
AVEO Pharmaceuticals Inc. 5.41M 29.12 5.33M -0.20 0.00

Table 1 demonstrates PolarityTE Inc. and AVEO Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 represents PolarityTE Inc. (NASDAQ:PTE) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
PolarityTE Inc. -2,735.40% -288% -120.8%
AVEO Pharmaceuticals Inc. -98.52% 48.1% -69.9%

Risk & Volatility

PolarityTE Inc. has a 1.25 beta, while its volatility is 25.00% which is more volatile than Standard and Poor’s 500. Competitively, AVEO Pharmaceuticals Inc. is 13.00% more volatile than Standard and Poor’s 500, because of the 1.13 beta.


PolarityTE Inc.’s Current Ratio and Quick Ratio are 13.8 and 13.7 respectively. The Current Ratio and Quick Ratio of its competitor AVEO Pharmaceuticals Inc. are 1.1 and 1.1 respectively. PolarityTE Inc. therefore has a better chance of paying off short and long-term obligations compared to AVEO Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for PolarityTE Inc. and AVEO Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PolarityTE Inc. 0 0 0 0.00
AVEO Pharmaceuticals Inc. 0 2 1 2.33

Competitively AVEO Pharmaceuticals Inc. has a consensus target price of $2, with potential upside of 104.08%.

Insider and Institutional Ownership

The shares of both PolarityTE Inc. and AVEO Pharmaceuticals Inc. are owned by institutional investors at 56.5% and 41.9% respectively. About 35.5% of PolarityTE Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.3% of AVEO Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PolarityTE Inc. 15.64% -17.38% 1.17% -51.67% -25.61% 8.52%
AVEO Pharmaceuticals Inc. -15.19% -19.85% -72.92% -80.67% -80.4% -64.96%

For the past year PolarityTE Inc. had bullish trend while AVEO Pharmaceuticals Inc. had bearish trend.


On 8 of the 11 factors AVEO Pharmaceuticals Inc. beats PolarityTE Inc.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.